Evidence map›Paper›PMID 30814998›Full record

ArticleFrontiers in immunology2019

Evidence for Highly Variable, Region-Specific Patterns of T-Cell Epitope Mutations Accumulating in

Arunachalam Ramaiah, Soumya Nayak, Srabanti Rakshit, Abigail L Manson, Thomas Abeel, Sivakumar Shanmugam, Pravat Nalini Sahoo, Anto Jesuraj Uday Kumar John, Jagadish Chandrabose Sundaramurthi, Sujatha Narayanan and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. RNA vaccines: The dawn of a new age for tuberculosis?Human vaccines & immunotherapeutics · 2025
    Review
  2. Article
  3. Article
  4. Evolutionary Genetics ofMicroorganisms · 2021
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 5 countries.

Arunachalam RamaiahCentre for Infectious Disease Research, Indian Institute of Science, Bangalore, India.
Soumya NayakCentre for Infectious Disease Research, Indian Institute of Science, Bangalore, India.
Srabanti RakshitCentre for Infectious Disease Research, Indian Institute of Science, Bangalore, India.
Abigail L MansonBroad Institute of MIT and Harvard, Cambridge, MA, United States.
Thomas AbeelBroad Institute of MIT and Harvard, Cambridge, MA, United States.
Sivakumar ShanmugamNational Institute for Research in Tuberculosis (ICMR), Chennai, India.
Pravat Nalini SahooCentre for Infectious Disease Research, Indian Institute of Science, Bangalore, India.
Anto Jesuraj Uday Kumar JohnDepartment of Pulmonary Medicine, St. John's Research Institute, Bangalore, India.
Jagadish Chandrabose SundaramurthiNational Institute for Research in Tuberculosis (ICMR), Chennai, India.
Sujatha NarayananNational Institute for Research in Tuberculosis (ICMR), Chennai, India.
George D'SouzaDepartment of Pulmonary Medicine, St. John's Research Institute, Bangalore, India.
Paul von HoegenJPT Peptide Technologies GmbH, Berlin, Germany.
Tom H M OttenhoffDepartment of Infectious Diseases, Leiden University Medical Center, Leiden, Netherlands.
Soumya SwaminathanNational Institute for Research in Tuberculosis (ICMR), Chennai, India.
Ashlee M EarlBroad Institute of MIT and Harvard, Cambridge, MA, United States.
Annapurna VyakarnamCentre for Infectious Disease Research, Indian Institute of Science, Bangalore, India.
Indian Institute of Science Bangalore · INNational Institute of Research in Tuberculosis · INBroad Institute · USSt. John's National Academy of Health Sciences · INJPT Peptide Technologies (Germany) · DELeiden University Medical Center · NL

Funding

LC: HIV Vaccine Trials NetworkUM1AI068618 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Margaret Juliana McElrath · 2011 to 2026
$483.6M
NIAID NIH HHS UM1 AI068618
6 · The paper itself

Abstract

Vaccines that confer protection through induction of adaptive T-cell immunity rely on understanding T-cell epitope (TCE) evolution induced by immune escape. This is poorly understood in tuberculosis (TB), an ancient, chronic disease, where CD4 T-cell immunity is of recognized importance. We probed 905 functionally validated, curated human CD4 T cell epitopes in 79

Indexed as

AllelesAntigenic VariationAntigens, BacterialBiological EvolutionEpitopes, T-LymphocyteGenome, BacterialGenomicsHistocompatibility Antigens Class IIHost-Pathogen InteractionsHumansImmunity, CellularIndiaInterferon-gammaMutationMycobacterium tuberculosisPhylogenyAntigens, BacterialEpitopes, T-LymphocyteHistocompatibility Antigens Class IIInterferon-gammaevolutiongenome sequenceimmune responseMycobacterium tuberculosisTB vaccineT-cell epitopes

Identifiers

PMID30814998
PMCPMC6381025
OpenAlexW2912104974

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.